Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.

Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL.

J Clin Oncol. 2019 Feb 1;37(4):336-349. doi: 10.1200/JCO.18.00729. Epub 2018 Dec 17.

PMID:
30707056
2.

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Jan 31:JCO1802037. doi: 10.1200/JCO.18.02037. [Epub ahead of print] No abstract available.

PMID:
30702028
3.

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00122. Epub 2018 Jul 11.

4.

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.

Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA.

J Immunother Cancer. 2018 Oct 19;6(1):108. doi: 10.1186/s40425-018-0426-7.

5.

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.

Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA.

J Clin Oncol. 2019 Jan 1;37(1):72-80. doi: 10.1200/JCO.18.00145. Epub 2018 Oct 19.

6.

Accelerating anticancer drug development - opportunities and trade-offs.

Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL.

Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Review.

PMID:
30275514
7.

Global Challenges for Cancer Imaging.

Schlemmer HP, Bittencourt LK, D'Anastasi M, Domingues R, Khong PL, Lockhat Z, Muellner A, Reiser MF, Schilsky RL, Hricak H.

J Glob Oncol. 2018 Sep;(4):1-10. doi: 10.1200/JGO.17.00036. Epub 2017 Sep 8.

8.

In Memoriam: James Frederick Holland, 1925 to 2018.

Silverman LR, Norton L, Schilsky RL.

J Clin Oncol. 2018 Sep 10;36(26):2665-2668. doi: 10.1200/JCO.18.00144. Epub 2018 Jul 27. No abstract available.

PMID:
30052481
9.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
10.

A New Look at the State of Cancer Care in America.

Polite BN, Seid JE, Levit LA, Kirkwood MK, Schenkel C, Bruinooge SS, Grubbs SS, Kamin DY, Schilsky RL.

J Oncol Pract. 2018 Jul;14(7):397-399. doi: 10.1200/JOP.18.00150. Epub 2018 Jun 15. No abstract available.

PMID:
29906212
11.

The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey.

Kirkwood MK, Hanley A, Bruinooge SS, Garrett-Mayer E, Levit LA, Schenkel C, Seid JE, Polite BN, Schilsky RL.

J Oncol Pract. 2018 Jul;14(7):e412-e420. doi: 10.1200/JOP.18.00149. Epub 2018 Jun 15.

PMID:
29906211
12.

Access versus evidence: The regulators' dilemma.

Schilsky RL.

Clin Trials. 2018 Jun;15(3):240-242. doi: 10.1177/1740774518770660. No abstract available.

PMID:
29871504
13.

Reply to S.D. Lucio.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Jul 10;36(20):2127. doi: 10.1200/JCO.2018.79.1780. Epub 2018 May 30. No abstract available.

PMID:
29847292
14.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

N Engl J Med. 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125. No abstract available.

PMID:
29791832
15.

A New IDEA in Adjuvant Chemotherapy for Colon Cancer.

Schilsky RL.

N Engl J Med. 2018 Mar 29;378(13):1242-1244. doi: 10.1056/NEJMe1800419. No abstract available.

PMID:
29590539
16.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.

PMID:
29504847
17.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253. doi: 10.5858/arpa.2018-0901-SA. Epub 2018 Mar 5.

PMID:
29504834
18.

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14.

PMID:
29443651
19.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H.

J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30.

PMID:
29380678
20.

Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?

Schnipper LE, Schilsky RL.

JAMA Oncol. 2018 Mar 1;4(3):333-334. doi: 10.1001/jamaoncol.2017.4339. No abstract available.

PMID:
29285543
21.

The evidence framework for precision cancer medicine.

Moscow JA, Fojo T, Schilsky RL.

Nat Rev Clin Oncol. 2018 Mar;15(3):183-192. doi: 10.1038/nrclinonc.2017.186. Epub 2017 Dec 19. Review.

PMID:
29255239
22.

Hans Christian Andersen and the Value of New Cancer Treatments.

Schilsky RL, Schnipper LE.

J Natl Cancer Inst. 2018 May 1;110(5):441-442. doi: 10.1093/jnci/djx261. No abstract available.

PMID:
29244175
23.

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM.

J Clin Oncol. 2018 Feb 20;36(6):617-623. doi: 10.1200/JCO.2017.75.8193. Epub 2017 Dec 13. No abstract available.

PMID:
29236570
24.

Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus.

Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI.

Cell. 2017 Nov 16;171(5):982-986. doi: 10.1016/j.cell.2017.10.032.

25.

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL.

J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.

26.

Guideposts on the journey to value.

Schilsky RL.

Ann Oncol. 2017 Oct 1;28(10):2325-2326. doi: 10.1093/annonc/mdx311. No abstract available.

PMID:
28961824
27.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

28.

Converging on the Value of Value Frameworks.

Schnipper LE, Schilsky RL.

J Clin Oncol. 2017 Aug 20;35(24):2732-2734. doi: 10.1200/JCO.2017.73.5704. Epub 2017 Jun 6. No abstract available.

PMID:
28586244
29.

Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al.

Schnipper LE, Schilsky RL.

J Clin Oncol. 2017 Apr 1;35(10):1134. doi: 10.1200/JCO.2016.70.9246. Epub 2017 Feb 6. No abstract available.

PMID:
28165893
30.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
31.

Reply to L. Casadaban et al.

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2017 Apr 20;35(12):1373-1374. doi: 10.1200/JCO.2016.71.2646. Epub 2017 Jan 23. No abstract available.

PMID:
28113023
32.

Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge.

Schilsky RL.

J Am Coll Surg. 2017 Jan;224(1):1-7. doi: 10.1016/j.jamcollsurg.2016.10.025. Epub 2016 Oct 28. No abstract available.

PMID:
27989954
33.

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE.

J Clin Oncol. 2016 Nov 20;34(33):3992-3999. doi: 10.1200/JCO.2016.67.7088. Epub 2016 Sep 30.

34.

Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.

Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Barron JJ, Malin JL, Rosenberg A, Schilsky RL, Lyman GH.

J Clin Oncol. 2016 Nov 10;34(32):3872-3879. doi: 10.1200/JCO.2016.67.2899. Epub 2016 Sep 30.

PMID:
27646945
35.

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.

36.

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R.

JAMA Oncol. 2016 Nov 1;2(11):1452-1459. doi: 10.1001/jamaoncol.2016.2129.

PMID:
27273579
37.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL.

J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31. No abstract available.

PMID:
27247218
38.

Transformation of Health Care - Perspectives of Opinion Leaders.

Disch J, Feeley TW, Mason DJ, Schilsky RL, Stovall EL, Nasso SF.

Semin Oncol Nurs. 2016 May;32(2):172-82. doi: 10.1016/j.soncn.2016.03.001. Epub 2016 Mar 8. No abstract available.

PMID:
27137474
39.

Response.

Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R.

J Natl Cancer Inst. 2016 Feb 24;108(3):djw001. doi: 10.1093/jnci/djw001. Print 2016 Mar. No abstract available.

PMID:
26912651
40.

Gains Against Cancer, But Enter 'Financial Toxicity'.

Schilsky RL, Wehrwein P.

Manag Care. 2015 Oct;24(10):46-7, 52-4. No abstract available.

41.
42.

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.

Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL.

J Clin Oncol. 2016 Jan 10;34(2):179-85. doi: 10.1200/JCO.2015.63.9674. Epub 2015 Oct 5. Review.

PMID:
26438111
43.

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R.

J Natl Cancer Inst. 2015 Sep 15;107(11). pii: djv253. doi: 10.1093/jnci/djv253. Print 2015 Nov. Erratum in: J Natl Cancer Inst. 2016 Feb;108(2). pii: djv423. doi: 10.1093/jnci/djv423.

44.

Highlights from the 2015 WIN Symposium: novel targets, innovative agents, and advanced technologies-a WINning strategy?

Schilsky RL.

Ecancermedicalscience. 2015 Aug 13;9:564. doi: 10.3332/ecancer.2015.564. eCollection 2015.

45.

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R.

J Clin Oncol. 2015 Nov 10;33(32):3817-25. doi: 10.1200/JCO.2015.61.5997. Epub 2015 Aug 24. Review.

46.

Modernizing Eligibility Criteria for Molecularly Driven Trials.

Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL.

J Clin Oncol. 2015 Sep 1;33(25):2815-20. doi: 10.1200/JCO.2015.62.1854. Epub 2015 Jul 20.

PMID:
26195710
47.

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL, American Society of Clinical Oncology.

J Clin Oncol. 2015 Aug 10;33(23):2563-77. doi: 10.1200/JCO.2015.61.6706. Epub 2015 Jun 22. No abstract available.

48.

Integrating biomarkers in colorectal cancer trials in the West and China.

Tejpar S, Shen L, Wang X, Schilsky RL.

Nat Rev Clin Oncol. 2015 Sep;12(9):553-60. doi: 10.1038/nrclinonc.2015.88. Epub 2015 May 12. Review.

PMID:
25963094
49.

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B.

Invest New Drugs. 2015 Aug;33(4):901-10. doi: 10.1007/s10637-015-0247-1. Epub 2015 May 8.

PMID:
25947566
50.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

Supplemental Content

Loading ...
Support Center